News

Data from the recently completed Phase 2 trial of Resunab (JBT-101) for cystic fibrosis (CF) treatment will be available by March 31, Corbus Pharmaceuticals has announced. The study (NCT02465450) included 85 patients who were treated at CF centers in the United States, Belgium, France, Germany, Italy, Poland and…

The University of Pittsburgh has agreed to conduct a Phase 1 and 2 clinical trial of Aries Pharmaceuticals‘ AIR001 for treating Pseudomonas aeruginosa bacteria infections in patients with cystic fibrosis (CF). Researchers from the university and the University of Pittsburgh Medical Center will work together on the open-label safety and proof-of-concept trial. Aries, a…

Vertex Pharmaceuticals is acquiring CTP-656, a potentiator treatment for the protein that is defective in cystic fibrosis, from Concert Pharmaceuticals. CTP-656, a deuterium-modified version of the therapy ivacaftor, is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, meaning that it enhances the activity of the CFTR protein. CTP-656 has received…

Treatment with hyertonic saline administered before airway clearance is no more effective than when administered during airway clearance in cystic fibrosis, found a study published in BMJ Open Respiratory Research.

PTC Therapeutics’ ataluren has failed to significantly improve respiratory function in nonsense mutation cystic fibrosis (nmCF), a severe form of the disease, according to results of a Phase 3 clinical trial. “We are disappointed with the outcome of this trial as there are no treatments that target the underlying cause…

Sizable doses of a powerful class of antibiotics used to treat cystic fibrosis (CF) can accumulate over time to increase the risk of permanent hearing loss, according to a study. Previous research had shown an association between aminoglycosides and hearing loss. The new study is the first to address both daily…

Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of the novel drugs GLPG2222 (a corrector) and GLPG2451 (a potentiator), the Belgian company Galapagos announced. The randomized, placebo-controlled study (NCT02788721) involves at least 40 healthy participants in Belgium.

Spyryx Biosciences has marked Feb. 28, Rare Disease Day, by announcing it will initiate a Phase 1b study to assess the safety of its SPX-101 in cystic fibrosis (CF) patients. SPX-101 is an experimental peptide designed to block the function of the lungs’ sodium channels, which move sodium and water from the…

The investigative oral treatment Resunab (JBT-101) shows promise in easing inflammation mediated by immune cells in the lungs of cystic fibrosis (CF) patients, according to results of a preclinical study. Results from a Phase 2 study of the treatment’s safety and efficacy in patients are expected shortly. The preclinical findings will be presented at Research and Development…

Kalydeco (ivacaftor) is known to increase the activity of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients. A new study says the drug also improves lung function and reduces inflammation, but does not eradicate Pseudomonas bacteria infection. The study, “Restoring CFTR Function Reduces Airway Bacteria…